Major advancements in pulmonary fibrosis treatment and critical warnings regarding both indoor air quality and scientific ...

Israeli researchers at a blood cancer conference in the US reported a lymphoma treatment that can achieve 100% survival rates ...

Please provide your email address to receive an email when new articles are posted on . Five factors were identified as reasons why patients avoid treatment with adalimumab and other biologics.

When Howard Chang, 50, first learned about biologic treatments for psoriasis almost 20 years ago, he was eager to give them a try. Now they’re a mainstay in his overall treatment plan. Chang was first ...

Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

A review of literature published over the last 5 years on ustekinumab in Crohn disease (CD) summarized 42 clinical studies on the efficacy and safety of ustekinumab products, including biosimilars, ...

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa (HS ...

Your diarrhea is back. You’ve spotted blood in your poop. And you’re tired all the time. It could be an ulcerative colitis (UC) flare. Ask your doctor about biologic or biosimilar therapies for ...

Smoking, higher body mass index (BMI), and previous exposure to biologics were linked to poorer responses to biologics among patients with psoriasis, in a meta-analysis. Older age (odds ratio [OR], ...

Biologic treatments are a new option for people with moderate to severe eczema or atopic dermatitis. Most people can control eczema with prevention techniques, topical treatments, or ultraviolet ...

Early initiation of biologic therapy in patients with Crohn’s disease (CD) is associated with higher rates of transmural healing and leads to improved long-term outcomes. In CD, early initiation of ...